Wilmington, NC – March 16, 2016 – AAIPharma Services Corporation (AAI) / Cambridge Major Laboratories, Inc. (CML), a leading provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, today announces its new brand and identity as a leading contract development and manufacturing organization (CDMO) with expanded capabilities and capacity, the organization to now be known as “Alcami”.
Originally joined together in late 2013, AAI and CML combined to offer analytical testing and development services for active pharmaceutical ingredients (APIs) with oral solid and parenteral dose finished product capacity. Providing an integrated offering for both drug substance and drug product at every development stage beginning with solid state chemistry and formulation development, Alcami believes they have created a robust new outsourcing offering.
Alcami has recently announced significant investments in additional capabilities and capacity for oral solid dose manufacturing, and parenteral fill-finish capabilities and capacity, including additional sterile lines and lyophilization capacity available now. Additionally, Alcami will be relocating its current St. Louis Analytical Testing Services to a new state of the art facility at the Cortex Innovation Center in St. Louis, MO, which provides innovative analytical testing solutions for manufacturers’ new drug entities, generic drugs, animal health products, medicated consumer health products, chemicals and biopharmaceuticals.
Stephan Kutzer, Chief Executive Officer stated “With nearly 1000 employees at seven sites in the United States and Europe, these upgrades across our facilities in Wilmington, Charleston, Durham, Germantown, Edison, St. Louis, and Weert, The Netherlands, combined with enhancements in our quality, execution and customer focus, support the overall progress of our growth strategy as a contract services provider with a renewed commitment to meeting customer needs like never before. With increases in our capabilities and capacities across all our businesses, our ability to serve the market is stronger than ever.”
Alcami represents the combination of the legacy company names in a contemporary coined name reflective of our transformation to become a world class solution provider to meet the growing pipeline of new products in development within the pharmaceutical & biotech industry. It is our commitment to ensure we work seamlessly and tirelessly to ensure we aid in the clinical progression and commercialization of medicines for our customers.
AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. have joined to form Alcami, a world class supplier of comprehensive pharmaceutical development and manufacturing services. With seven sites across the globe, our combined capabilities include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid dose and parenteral), packaging, and stability services.
Contact: Catherine Hanley